Consideration of endogenous backgrounds in pharmacokinetic analyses: a simulation study

被引:11
作者
Schindel, F [1 ]
机构
[1] Aventis Behring GmbH, Biometr Dept, D-35002 Marburg, Germany
关键词
pharmacokinetics; biologic compounds; endogenous background;
D O I
10.1007/s002280000230
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The pharmacokinetic analysis of biologic compounds is frequently disturbed by the presence of endogenous levels, which cannot be discerned from exogenous levels. The frequently used method of subtracting baseline levels from subsequent measurements was compared to a fully adjusted regression model in a simulation study. Methods: Simulations (5,000 each) were carried out for a standard one-compartment model with rich (n = 10) and poor (n = 6) postdose sampling, using unweighted as well as two-weighted types of non-linear regression. Results: Whereas the fully adjusted model performed properly across various scenarios, the subtraction method showed a noteworthy bias (up to 14%) for area under the curve (AUC) and elimination half-life with weighted non-linear regression. For estimation of the C-max parameter using any weighting scheme, and of any parameter using unweighted non-linear regression, the two methods performed equally well. As expected, poor in contrast to rich sampling resulted in larger coefficients of variation, but also in increasing failures (4.4%) of the regression algorithm (failure to converge, negative C-max or half-life) for the subtraction method when it was combined with the weighting scheme giving highest weight to small concentrations. Conclusion: The risk of biased results may result from the subtraction method, which may also affect the analysis of dose linearity, bioequivalence and population kinetic studies with biologic compounds. When background endogenous levels are not negligible, a fully adjusted model is recommended.
引用
收藏
页码:685 / 688
页数:4
相关论文
共 7 条
[1]  
COOK RD, 1986, BIOMETRIKA, V73, P615
[2]  
*FDA DIV BIOEQ, 1992, 070192 IHS BIO
[3]   PHARMACOKINETICS AND ERYTHROPOIETIC RESPONSE TO HUMAN RECOMBINANT ERYTHROPOIETIN IN HEALTHY-MEN [J].
FLAHARTY, KK ;
CARO, J ;
ERSLEV, A ;
WHALEN, JJ ;
MORRIS, EM ;
BJORNSSON, TD ;
VLASSES, PH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (05) :557-564
[4]   PHARMACOKINETICS OF ENDOGENOUS SUBSTANCES - SOME PROBLEMS AND SOME SOLUTIONS [J].
MARZO, A ;
RESCIGNO, A .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1993, 18 (01) :77-88
[5]   MULTI-VARIATE ANALYSIS OF FACTORS GOVERNING THE PHARMACOKINETICS OF EXOGENOUS FACTOR-VIII IN HEMOPHILIACS [J].
MESSORI, A ;
LONGO, G ;
MORFINI, M ;
CINOTTI, S ;
FILIMBERTI, E ;
GIUSTARINI, G ;
FERRINI, PR .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (06) :663-668
[6]   Design of biological equivalence programs for therapeutic biotechnology products in clinical development: A perspective [J].
Mordenti, J ;
Cavagnaro, JA ;
Green, JD .
PHARMACEUTICAL RESEARCH, 1996, 13 (10) :1427-1437
[7]  
*PHARS CORP, 1998, WINN STAND ED 3 0 RE